ReviewBlood cancer journal2021
Extramedullary disease in multiple myeloma.
Review in Blood cancer journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Outcomes in patients with relapsed/refractory multiple myeloma with extramedullary disease: a meta-analysis.Annals of hematology · 2025Pooled it
- Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease.Journal of hematology & oncology · 2022Trial
- Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma.Blood advances · 2026Article
- A single-arm prospective phase I trial of 68Ga-PFBC01 PET/CT for multiple myeloma B cell maturation antigen imaging.The Journal of clinical investigation · 2026Article
- Factors Affecting Prognosis in Patients with Extramedullary Myeloma: A Single-Center Experience.Journal of clinical medicine · 2026Article
- Tympanic Membrane Involvement of Multiple Myeloma: Report of a Case.Hematology reports · 2026Article
- Article
- Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.Cancer medicine · 2026Article
- Article
- Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis.Annals of hematology · 2026Article
- Clinical presentation and treatment of plasmablastic myeloma-a multicenter retrospective analysis.Discover oncology · 2026Article
- Testicular Plasmacytoma as the First Manifestation of Systemic Multiple Myeloma.Diagnostics (Basel, Switzerland) · 2026Article
- Bilateral breast plasmacytomas in a male patient with relapsed multiple myeloma: A case report.Radiology case reports · 2026Article
- Secondary Cutaneous Plasmacytoma as a Manifestation of Extramedullary Multiple Myeloma: A Case Report.Cureus · 2026Article
- Extramedullary Disease-Achilles Heel in Myeloma?American journal of hematology · 2026Review
- Growth differentiation factor 15 promotes the malignant progression of multiple myeloma via activation of PI3K/Akt/NF-κB signaling pathway.Journal of translational medicine · 2026Article
- Fulminant extramedullary relapse of multiple myeloma with rare cardiac, vascular, and multivisceral involvement: A case report.Therapeutic advances in hematology · 2026Article
- Clinicopathological Features and Prognostic Differences Between Primary and Relapsed or Refractory Extramedullary Multiple Myeloma.Cancer management and research · 2026Article
- Knowledge, Attitudes, and Practices Among Patients with Multiple Myeloma: A Cross‑Sectional Study Using Structural Equation Modeling in a Single Tertiary Hospital in Wenzhou, China.Patient preference and adherence · 2026Article
- Case Report: Cytoreductive surgery as a therapeutic attempt in the treatment of extramedullary plasmacytoma.Frontiers in surgery · 2026Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When clonal plasma cells grow at anatomic sites distant from the bone marrow or grows contiguous from osseous lesions that break through the cortical bone, it is referred to as extramedullary multiple myeloma (EMD). EMD remains challenging from a therapeutic and biological perspective. The pathogenetic mechanisms are not completely understood and it is generally associated with high-risk cytogenetics which portends poor outcomes. There is a rising incidence of EMD in the era of novel agents, likely a reflection of longer OS, with no standard treatment approach. Patients benefit from aggressive chemotherapy-based approaches, but the OS and prognosis remains poor. RT has been used for palliative care. There is a need for large prospective trials for development of treatment approaches for treatment of EMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.